Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist

Author： Bauman John  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 662-671

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Asenapine Pharmacokinetics in Hepatic and Renal Impairment

By Peeters Pierre  

Clinical Pharmacokinetics, Vol. 50, Iss. 7, 2011-07 ,pp. : 471-481

Adis International

Access to resources Recommend Favorite

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

By Boulton David W.   Li Li   Frevert Ernst U.   Tang Angela   Castaneda Lorna   Vachharajani Nimish N.   Kornhauser David M.   Patel Chirag G.  

Clinical Pharmacokinetics, Vol. 50, Iss. 4, 2011-04 ,pp. : 253-265

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

By Weil Angelika  

Clinical Pharmacokinetics, Vol. 49, Iss. 9, 2010-09 ,pp. : 607-618

Adis International

Access to resources Recommend Favorite

Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole

By Mallikaarjun Suresh  

Clinical Pharmacokinetics, Vol. 47, Iss. 8, 2008-01 ,pp. : 533-542

Adis International

Access to resources Recommend Favorite

Aprepitant – a novel NK1-receptor antagonist

By Patel Lisa   Lindley Celeste  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 12, 2003-12 ,pp. : 2279-2296

Informa Healthcare

Access to resources Recommend Favorite